Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2019, vol. 28, nr 1, January, p. 51–58

doi: 10.17219/acem/76262

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Non-classical and intermediate monocytes in patients following venous thromboembolism: Links with inflammation

Ewa Wypasek1,2,A,C,D, Agnieszka Padjas2,B,C,D, Magdalena Szymańska3,B,C, Krzysztof Plens4,C, Maciej Siedlar5,E,F, Anetta Undas1,A,E,F

1 Institute of Cardiology, Jagiellonian University Medical College, Kraków, Poland

2 Department of Medicine, Jagiellonian University Medical College, Kraków, Poland

3 John Paul II Hospital, Kraków, Poland

4 Data Analysis Center, Cardiovascular Research Institute, Kraków, Poland

5 Department of Clinical Immunology, Chair of Clinical Immunology and Transplantation, Institute of Pediatrics, Jagiellonian University Medical College, Kraków, Poland

Abstract

Background. Monocyte subsets are involved in atherosclerotic vascular disease and its thromboembolic complications. Moreover, the role of monocytes has been suggested in the pathogenesis of venous thromboembolism (VTE).
Objectives. We hypothesized that pro-inflammatory non-classical and intermediate monocytes are increased in the first months following VTE.
Material and Methods. We enrolled 70 patients aged 18–65 years (mean age 41.6 ±11.6) with the firstever provoked (n = 32; 45.7%) or unprovoked (n = 38; 54.28%) VTE episode, and 46 healthy controls. The exclusion criteria were: acute infection, cancer, autoimmune disorders, previous myocardial infarction (MI), or stroke. Monocyte subsets were assessed 12 (8.5–21.5) months after VTE using flow cytometry and were defined as classical (CD14++CD16–), intermediate (CD14++CD16+) and non-classical (CD14+CD16++).
Results. Patients with VTE had higher intermediate and non-classical monocyte counts compared to the control group (16.8 ±9.3 vs 10.4 ±4.0 cells/μL, and 64.1 ±25.2 vs 44.1 ±19.2 cells/μL, respectively, both p < 0.001). Increased non-classical monocyte counts were observed in patients who experienced a VTE incident within 12 months prior to enrollment (71.5 ±27.4 vs 56.03 ±20.6 cells/μL; p = 0.01) and those with unprovoked VTE (70.2 ±4.1 vs 58.8 ±4.3 cells/μL; p = 0.06). There were no differences in monocyte subsets related to the current anticoagulation.
Conclusion. Our data has shown for the first time that VTE is associated with an increased number of nonclassical and intermediate monocytes, which may indicate the involvement of monocyte-related mechanisms in the pathophysiology of this disease.

Key words

inflammation, venous thromboembolism, non-classical monocytes, intermediate monocytes

References (48)

  1. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14.
  2. Zhu T, Martinez I, Emmerich J. Venous thromboembolism risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29(3):298–310.
  3. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007;44(2):62–69.
  4. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep veins thrombosis. Lancet. 2012;379(9828):1835–1846.
  5. Folsom AR, Lutsey PL, Astor BC, Cushman M. C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost. 2009;102(4):615–619.
  6. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol. 2010;30(8):1672–1678.
  7. Roumen-Klappe EM, den Heijer M, van Uum SH, van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg. 2002;35(4):701–716.
  8. Pesavento R, Villalta S, Prandoni P. The post-thrombotic syndrome. Intern Emerg Med. 2010;5(3):185–192.
  9. Rabinovich A, Kahn SR. How to predict and diagnose postthrombotic syndrome. Pol Arch Med Wewn. 2014;124(7–8):410–416.
  10. Bucek RA, Reiter M, Quehenberger P, Minar E. C-reactive protein in the diagnosis of deep vein thrombosis. Br J Haematol. 2002;119(2):385–389.
  11. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367(9516):1075–1079.
  12. Rabinovich A, Cohen JM, Cushman M. BioSOX Investigators. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2015;3(4):347–353.
  13. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2013;13(1):34–45.
  14. von Bruhl ML, Stark K, Steinhart A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819–835.
  15. Pfeiler S, Massberg S, Engelmann B. Biological basis and pathological relevance of microvascular thrombosis. Thromb Res. 2014;133(Suppl 1):S35–37.
  16. van der Poll T, Herwald H. The coagulation system and its function in early immune defense. Thromb Haemost. 2014;112(4):640–648.
  17. Passlick B, Flieger D, Ziegler-Heitbrock HW. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 1989;74(7):2527–2534.
  18. Ziegler-Heitbrock L, Ancuta P, Crowe S , et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116(16):74–80.
  19. Ziegler-Heitbrock L. Blood monocytes and their subsets: Established features and open questions. Front Immunol. 2015;6:423.
  20. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J Immunol. 2002;168(7):3536–3542.
  21. Mukherjee R, Kanti Barman P, Kumar Thatoi P, Tripathy R, Kumar Das B, Ravindran B. Non-classical monocytes display inflammatory features: Validation in sepsis and systemic lupus erythematous. Sci Rep. 2015;5:13886.
  22. Schlitt A, Heine GH, Blankenberg S, et al. CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost. 2004;92(2):419–424.
  23. Imanishi T, Ikejima H, Tsujioka H, et al. Association of monocyte subset counts with coronary fibrous cap thickness in patients with unstable angina pectoris. Atherosclerosis. 2010;212(2):628–635.
  24. Rogacev KS, Cremers B, Zawada AM , et al. CD14++CD16+ monocytes independently predict cardiovascular events: A cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol. 2012;60(16):1512–1520.
  25. Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GY. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. J Thromb Haemost. 2012;10(7):1231–1241.
  26. Zeng S, Zhou X, Ge L, et al. Monocyte subsets and monocyte-platelet aggregates in patients with unstable angina. J Thromb Thrombolysis. 2014;38(4):439–446.
  27. Rothe G, Gabriel H, Kovacs E, et al. Peripheral blood mononuclear phagocyte subpopulations as cellular markers in hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1996;16(12):1437–1447.
  28. Kaito M, Araya S, Gondo Y, et al. Relevance of distinct monocyte subsets to clinical course of ischemic stroke patients. PLoS One. 2013;8(8):e69409.
  29. Maldonado-Peña J, Rivera K, Ortega C, Betancourt M, Lugo JE, Camargo E. Can monocytosis act as an independent variable for predicting deep vein thrombosis? Int J Cardiol. 2016;219:282–284.
  30. Go SI, Kim RB, Song HN, et al. Prognostic significance of the absolute monocyte counts in lung cancer patients with venous thromboembolism. Tumour Biol. 2015;36(10):7631–7639.
  31. Siedlar M, Strach M, Bukowska-Strakova K, et al. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Clin Immunol. 2011;139(2):122–132.
  32. Chow S, Shao J, Wang H. Sample Size Calculations in Clinical Research. 2nd ed. New York-Basel: Marcel Dekker Inc.; 2008.
  33. Riva N, Donadini MP, Ageno W. Epidemiology and pathophysiology of venous thromboembolism: Similarities with atherothrombosis and the role of inflammation. Thromb Haemost. 2015;113(6):1176–1183.
  34. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol. 2012;32(8):1777–1783.
  35. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15):1435–1441.
  36. Prandoni P, Ghirarduzzi A, Prins MH, et al. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. J Thromb Haemost. 2006;4(9):1891–1896.
  37. Sørensen HT, Horvath-Puho E, Pedersen L, et al. Venous thromboembolism and subsequent hospitalization due to acute arterial cardiovascular events: A 20 year cohort study. Lancet. 2007;370(9601):1773–1779.
  38. Gren ST, Rasmussen TB, Janciauskiene S, Håkansson K, Gerwien J, Grip O. A single-cell gene-expression profile reveals inter-cellular heterogeneity within human monocyte subsets. PLoS One. 2015;10(12):e0144351.
  39. Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol. 2006;80(5):1156–1164.
  40. Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163(3):740–745.
  41. van der Poll T, Levi M, Büller HR, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med. 1991;174(3):729–732.
  42. Hearps AC, Martin GE, Angelovich TA, et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. Aging Cell. 2012;11(5):867–875.
  43. Puchta A, Naidoo A, Verschoor CP, et al. TNF drives monocyte dysfunction with age and results in impaired anti-pneumococcal immunity. PLoS Pathog. 2016;12(1):e1005368.
  44. Poitou C, Dalmas E, Renovato M, et al. CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: Relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(10):2322–2330.
  45. Rogacev KS, Ulrich C, Blomer L, et al. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J. 2010;31(3):369–376.
  46. Kawanaka N, Yamamura M, Aita T, et al. CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2002;46(10):2578–2586.
  47. Myśliwska J, Smardzewski M, Marek-Trzonkowska N, Myśliwiec M, Raczyńska K. Expansion of CD14+CD16+ monocytes producing TNF-α in complication-free diabetes type 1 juvenile onset patients. Cytokine. 2012;60(1):309–317.
  48. Montagnana M, Danese E, Lippi G. Genetic risk factors of atherothrombosis. Pol Arch Med Wewn. 2014;124(9):474–482.
© Wroclaw Medical University